Open AccessLong-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Author(s) -
Bruce A.C. Cree,
Krzysztof Selmaj,
Lawrence Steinman,
Gıancarlo Comı,
Amit BarOr,
Douglas L. Arnold,
HansPeter Hartung,
Xavier Montalbán,
Eva Havrdová,
James Sheffield,
Neil Minton,
Chun-Yen Cheng,
Diego Augusto Santos Silva,
Ludwig Kappos,
Jeffrey A. Cohen
Publication year - 2022
Publication title -
multiple sclerosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.729
H-Index - 131
eISSN - 1477-0970
pISSN - 1352-4585
DOI - 10.1177/13524585221102584
Subject(s) - medicine , adverse effect , tolerability , pediatrics
Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS.